Dimensional Fund Advisors LP Boosts Holdings in Glaukos Co. (NYSE:GKOS)

Dimensional Fund Advisors LP increased its position in shares of Glaukos Co. (NYSE:GKOS) by 9.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 312,314 shares of the medical instruments supplier’s stock after purchasing an additional 26,540 shares during the period. Dimensional Fund Advisors LP owned approximately 0.57% of Glaukos worth $46,828,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in GKOS. IFP Advisors Inc purchased a new position in shares of Glaukos during the fourth quarter valued at approximately $43,000. Asset Planning Inc bought a new position in Glaukos in the 4th quarter valued at $90,000. Picton Mahoney Asset Management purchased a new stake in Glaukos in the fourth quarter worth $125,000. SBI Securities Co. Ltd. bought a new stake in shares of Glaukos during the fourth quarter worth $153,000. Finally, Smartleaf Asset Management LLC lifted its position in shares of Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock worth $164,000 after purchasing an additional 807 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Truist Financial reiterated a “buy” rating and set a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a report on Thursday. Stifel Nicolaus cut their price target on Glaukos from $140.00 to $115.00 and set a “buy” rating on the stock in a research note on Thursday. Wells Fargo & Company lowered shares of Glaukos from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $160.00 to $86.00 in a research note on Thursday. Stephens cut their target price on shares of Glaukos from $140.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Mizuho lowered their price target on shares of Glaukos from $200.00 to $175.00 and set an “outperform” rating for the company in a research report on Wednesday, April 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $137.62.

Insider Buying and Selling

In related news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 1,520 shares of the business’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

Glaukos Trading Up 4.9 %

Shares of Glaukos stock opened at $87.60 on Friday. The firm’s 50 day simple moving average is $97.60 and its two-hundred day simple moving average is $128.81. Glaukos Co. has a 12-month low of $77.10 and a 12-month high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $5.00 billion, a price-to-earnings ratio of -30.52 and a beta of 0.88.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $106.66 million during the quarter, compared to analysts’ expectations of $102.78 million. During the same period in the previous year, the business posted ($0.70) EPS. The business’s quarterly revenue was up 24.6% compared to the same quarter last year. Analysts predict that Glaukos Co. will post -1.08 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.